Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
DNA methylation is a molecular process that helps enable our bodies to repair themselves, fight infection, get rid of environmental toxins, and even to think. But sometimes this process goes awry.
Deaths from cirrhosis rose in all but one state between 1999-2016, with increases seen most often among young adults, a new study shows.
In an Addiction Biology study, the estimated prevalence of very high risk drinking level (VHRDL, defined as drinking >100 g of ethanol per day) in 13 European Union countries was 0.74-0.85 percent, with a risk of disease or injury of 13.5 per 100 people with VHRDL per year.
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis -- the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
Among the most serious consequences of the opioid epidemic is the spread of hepatitis C among injecting drug users.
One of the lines of research of the UPV/EHU's Lipids & Liver group, which focusses on the mechanisms involved in the development and progression of non-alcoholic fatty liver disease, is achieving significant advances in a range of aspects; these include the identification of proteins that alter the metabolic pathways in the development and progression of liver disease, and even cancer, and the seeking of targets to enable the disease to be reversed.
A simple $20 blood test could help diagnose thousands of patients with hepatitis B in need of treatment in some of Africa's poorest regions.
Chemical compounds produced by the bacteria in our gut could be used to spot the early stages of liver disease, according to new research.
According to a new study four cups of strong coffee might be the amount that would keep the hearts of older adults healthy. The latest study titled, “CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system—New mode of action for caffeine,” was published on 21st of June 2018 in the journal PLOS Biology.
An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention.
Researchers from Charité - Universitätsmedizin Berlin have successfully tested a new technology for use in the assessment of overweight adolescents with liver disease.
For patients who live in rural areas, driving to see a specialist in a large city or at a university hospital can be challenging, if not impossible.
New research led by Professor Catherine Williamson, School of Life Course Sciences, shows that using drugs to treat male mice with cholestasis reduced the likelihood of male offspring developing high blood pressure.
Changes to the immune system remain many years after a hepatitis C infection heals, a new study by researchers at Karolinska Institutet, Sweden, and Hannover Medical School, Germany, shows.
The number of insurance denials for life-saving hepatitis C drugs among patients with both private and public insurers remains high across the United States, researchers from the Perelman School of Medicine at the University of Pennsylvania reported in a new study published in the journal Open Forum Infectious Diseases.
Researchers at the University of Delaware, working with colleagues at Indiana University, have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced preliminary results from its ongoing Phase I study of small activating RNA candidate MTL-CEBPA in advanced liver cancer.
A research project performed at the universities of Jyväskylä and Turku studied the effects of a specific gut enterobacterium on body fat mass.
The University of Surrey has created a new mathematical model that details how the Hepatitis C infection develops and behaves more accurately than previous models. This new model has the potential to improve treatment for the infection that affects 215,000 people in the United Kingdom.
Scientists have developed a lab-based system for studying the most common type of liver disease, paving the way for research into new therapies.